West Oak Capital’s Nektar Therapeutics NKTR Stock Holding History

West Oak Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2	Closed	-$1K	–	370
2021 Q1	$1K	Hold	2	–	–	﹤0.01%	326
2020 Q4	$1K	Hold	2	–	–	﹤0.01%	303
2020 Q3	$0	Hold	2	–	–	﹤0.01%	319
2020 Q2	$1K	Hold	2	–	–	﹤0.01%	284
2020 Q1	$1K	Buy	+2	New	+$619	﹤0.01%	270

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

West Oak Capital's NKTR Position: Q2 2021 in Review

West Oak Capital sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 2 shares — an estimated $1K sold.

West Oak Capital first reported a position in NKTR in Q1 2020 and held it in 5 quarters. The position peaked at $1K in Q1 2021. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

West Oak Capital reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
West Oak Capital sold 2 Nektar Therapeutics shares in Q2 2021, an estimated $1K.
West Oak Capital first reported a position in Nektar Therapeutics in Q1 2020 and held it in 5 quarters.
West Oak Capital's Nektar Therapeutics position peaked at $1K in Q1 2021.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on West Oak Capital's 13F filing for Q2 2021, filed 20 Jul 2021.